DiaSorin SpA/ADR

DiaSorin SpA/ADR

DiaSorin was founded in 1968 in Saluggia, Italy, by Carlo Rosa's family, who still control the company through a majority stake. The firm went public on the Milan Stock Exchange in 2000 (ticker: DIA.MI) and has grown through organic innovation and strategic acquisitions, including the 2017 purchase of the diagnostic division of Finland's Thermo Fisher Scientific for $1.8B (per Reuters). The company focuses on immunodiagnostics and molecular diagnostics, with a product portfolio covering infectious diseases, thyroid function, fertility, oncology, and bone metabolism. DiaSorin operates manufacturing sites in Italy, the US (Stillwater, Minnesota), and Finland, and sells in over 60 countries. Its R&D investments are centered on the proprietary LIAISON line of analyzers, which offer automated testing for hospitals and reference labs. As of 2025, DiaSorin employs over 3,000 people globally. The company's ADR program, listed over-the-counter, allows US investors to trade its shares without direct access to the Milan exchange. The firm has not disclosed any family office structure separate from the operating company; the controlling Rosa family manages its wealth through the publicly traded entity. DiaSorin's structure is unusual for a diagnostics firm: it remains under family control while being a public company. The Rosa family holds a majority stake, giving them governance control alongside public minority shareholders. This hybrid governance model means the firm operates with a long-term orientation typical of family-owned businesses while accessing public capital markets.